ReviewJournal of the American College of Cardiology2021
Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week.
Review in Journal of the American College of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 6 syntheses or guidelines pooled it, 187 citations in OpenAlex.
- Cost-Utility Analyses of Systemic Treatments for Psoriasis and Psoriatic Arthritis in the UK: A Systematic Review of Modelling Methods.PharmacoEconomics · 2026Pooled it
- Integration of GWAS and single-cell analysis for psoriasis identifies disease-associated cell subtypes and therapeutic targets.Nature communications · 2026Pooled it
- Menopause and Common Dermatoses: A Systematic Review.American journal of clinical dermatology · 2026Pooled it
- Exploring the association between psoriasis and subclinical atherosclerosis defined by carotid intima-media thickness (CIMT) in patients with psoriasis vulgaris: a systematic review and meta-analysis.Irish journal of medical science · 2025Pooled it
- Subclinical Myocardial Dysfunction Assessment Using Speckle Tracking Echocardiography in Patients With Psoriasis: A Pilot Meta-Analysis.Clinical cardiology · 2024Pooled it
- Association between psoriasis and coronary artery calcification: A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.JAMA dermatology · 2026Trial
- Cutaneous adipose tissue carries a strong inflammatory signature in patients with psoriasis.JCI insight · 2026Trial
- Trial
- Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial.Cardiovascular research · 2024Trial
- Statin therapy upregulates arachidonic acid status via enhanced endogenous synthesis in patients with plaque psoriasis.Prostaglandins, leukotrienes, and essential fatty acids · 2022Trial
- Cumulative Duration of Severe Psoriasis: A Novel Cardiovascular Risk Predictor for Dermatologists.Dermatology and therapy · 2026Article
- Phenylalanine exacerbates psoriasiform inflammation through NF‑κB‑mediated dendritic cell activation and Th17 polarization.International journal of molecular medicine · 2026Article
- Unveiling the Immune Mechanisms of Hypertension With Single-Cell Transcriptome-Wide Mendelian Randomization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Relationship of Vitamin D, Spondyloarthritis Activity and Left Ventricular Systolic and Diastolic Function.Journal of clinical medicine · 2026Article
- TOLLIP Inhibits Psoriasis Progression via Suppressing PKM2-Mediated Glycolysis in Keratinocytes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Molybdenum Nanoparticles Alleviate Psoriasis-Related Cardiovascular Oxidative Stress and Inflammation.ACS omega · 2026Article
- Selected Vascular, Inflammatory, and Lipid Parameters in Patients with Selected Keratinization Disorders: Preliminary Data from a Retrospective Observational Study.Journal of clinical medicine · 2026Article
- The Gut-Oral-Skin-Heart Microbiota Axis and Oxidative Stress: Where Have We Been and Where Are We Going.Dermatology and therapy · 2026Review
- Skin as a sentinel and modulator of systemic aging: a translational framework for evidence-based gerotherapeutics.GeroScience · 2026Review
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Psoriasis is a chronic inflammatory skin disease that affects 2% to 3% of the U.S. population. The immune response in psoriasis includes enhanced activation of T cells and myeloid cells, platelet activation, and up-regulation of interferons, tumor necrosis factor-α, and interleukins (ILs) IL-23, IL-17, and IL-6, which are linked to vascular inflammation and atherosclerosis development. Patients with psoriasis are up to 50% more likely to develop cardiovascular disease (CV) disease, and this CV risk increases with skin severity. Major society guidelines now advocate incorporating a psoriasis diagnosis into CV risk prediction and prevention strategies. Although registry data suggest treatment targeting psoriasis skin disease reduces vascular inflammation and coronary plaque burden, and may reduce CV risk, randomized placebo-controlled trials are inconclusive to date. Further studies are required to define traditional CV risk factor goals, the optimal role of lipid-lowering and antiplatelet therapy, and targeted psoriasis therapies on CV risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.